Brief: Dream-Hf Phase 3 Trial Results For Mesoblast Cell Therapy In Heart Failure Published In Journal Of The American College Of Cardiology (Jacc)
27/02/2023 21:53
Feb 27 (Reuters) - Mesoblast Ltd MSB.AX :
* DREAM-HF PHASE 3 TRIAL RESULTS FOR MESOBLAST CELL THERAPY
IN
HEART FAILURE PUBLISHED IN JOURNAL OF THE AMERICAN COLLEGE OF
CARDIOLOGY (JACC)
Source text for Eikon: ID:nGNXMjkv0
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M